Jan Berglf - Bio Works CoFounder Advisor
| BIOWKS Stock | SEK 1.05 0.12 12.90% |
Insider
Jan Berglf is CoFounder Advisor of Bio Works Technologies AB
| Phone | 46 8 56 26 74 30 |
| Web | https://www.bio-works.com |
Bio Works Management Efficiency
The company has return on total asset (ROA) of (0.3486) % which means that it has lost $0.3486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6619) %, meaning that it generated substantial loss on money invested by shareholders. Bio Works' management efficiency ratios could be used to measure how well Bio Works manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thoas MD | Cantargia AB | 61 | |
| Linda Andersson | Genovis AB | 47 | |
| Martin mark | Xbrane Biopharma AB | 43 | |
| Ivan Astralaga | C Rad AB | N/A | |
| Emelie Gozzi | C Rad AB | N/A | |
| Adnan Deronic | Cantargia AB | N/A | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Johanna Christensen | Cantargia AB | N/A | |
| Patrik Hellberg | Intervacc AB | N/A | |
| Fredrik Olsson | Genovis AB | 52 | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Peter Madsen | Cantargia AB | N/A | |
| Dominique Tersago | Cantargia AB | 61 | |
| Susanne Ahlberg | Genovis AB | 66 | |
| Magnus Langberg | Genovis AB | 52 | |
| Lars Levin | C Rad AB | 52 | |
| Nina Ivers | Xbrane Biopharma AB | 53 | |
| Hakan Axelsson | C Rad AB | 55 | |
| Erik Domines | Xbrane Biopharma AB | 59 | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| Tim Thurn | C Rad AB | 42 | |
Management Performance
| Return On Equity | -0.66 | |||
| Return On Asset | -0.35 |
Bio Works Technologies Leadership Team
Elected by the shareholders, the Bio Works' board of directors comprises two types of representatives: Bio Works inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Works' management team and ensure that shareholders' interests are well served. Bio Works' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Works' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sara Ekvall, Director Culture | ||
| Anna Lindqvist, Chief Officer | ||
| Jonathan Royce, Chief Officer | ||
| David Nelander, Chief Officer | ||
| Helena Pahlm, Director Quality | ||
| Jan Berglf, CoFounder Advisor | ||
| Karsten Fjrstedt, Chief Officer |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Works a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | |||
| Return On Asset | -0.35 | |||
| Profit Margin | (1.31) % | |||
| Operating Margin | (1.27) % | |||
| Current Valuation | 635.01 M | |||
| Shares Outstanding | 34.87 M | |||
| Shares Owned By Insiders | 54.85 % | |||
| Shares Owned By Institutions | 5.59 % | |||
| Price To Book | 8.03 X | |||
| Price To Sales | 19.71 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Bio Stock
Bio Works financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Works security.